An optimized CXCR4-targeting peptide theranostic pair was developed for simultaneous PET imaging and therapeutic radionuclide delivery in CXCR4-expressing cancers.
Same peptide finds AND treatsOne peptide targets CXCR4 on cancer cells — labeled for imaging it finds tumors, labeled for therapy it irradiates them. Precision cancer medicine.
What the researchers found
Optimized CXCR4-targeting peptide theranostic pair: improved tumor uptake and imaging quality for diagnostic PET + therapeutic radionuclide delivery in CXCR4-expressing cancers.
Why it matters
The same peptide that finds cancer on a scan can deliver radiation to kill it — precision therapy guided by precision diagnosis.
How the study worked
Peptide optimization for CXCR4 targeting, dual labeling for PET imaging and therapeutic radionuclide, biodistribution, and imaging studies.
What this study cannot tell us
Preclinical optimization. Clinical translation pathway needed.
How to read the evidence
Preclinical theranostic optimization.
When this study was published
Published in 2025.
The bigger picture
Peptide-based theranostics are becoming standard for nuclear medicine cancer treatment, following the PRRT model success.
Questions still open
- Which CXCR4+ cancers would benefit most from this theranostic?
- How does this compare to existing CXCR4-targeting agents (Pentixafor)?
- Would the therapeutic partner achieve sufficient tumor radiation doses?
Common questions
What is a theranostic?
Which cancers express CXCR4?
Read the original research
Development of an Optimized CXCR4-Targeting Theranostic Pair.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Citation
Kwon, Daniel; Bloise, Ingrid; Zhang, Zhengxing; Colpo, Nadine; Wilson, Ryan; Tan, Ruiyan; Merkens, Helen; Zeisler, Jutta; Lau, Joseph; Lin, Kuo-Shyan; Bénard, François. (2026). Development of an Optimized CXCR4-Targeting Theranostic Pair.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.269933